Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS 7 Major Japan Drug Makers Net Two-Digit Growth in Combined H1 Sales on Flagship Brands, Upfront Income
November 4, 2021
-
BUSINESS Shionogi Wants to Pick Global Partner for Oral COVID-19 Drug by Year-End: President
November 2, 2021
-
BUSINESS Daiichi Sankyo Launches Oncolytic Virus Delytact in Japan
November 2, 2021
-
BUSINESS Hypertension OK Now in Hand, Novartis Expanding Entresto Pitch to GPs with Superior Efficacy over ARBs
November 1, 2021
-
BUSINESS Senju Gearing Up to Grow Lucentis Biosimilar into Its Mainstay Product
November 1, 2021
-
ORGANIZATION PhRMA Reserves Opinion on INES Proposal, but Says No to Any Cherry-Picking
October 29, 2021
-
REGULATORY Late-Phase Trials with Overseas Participation Pragmatic Approach for Japan-Made COVID-19 Vaccine Development: PMDA Director
October 29, 2021
-
REGULATORY Ronapreve Up for PAFSC Review for Preventive Use on Nov. 4
October 29, 2021
-
BUSINESS Sumitomo Dainippon to Speed Up Development of CNS Blockbuster Hopeful through Otsuka Alliance
October 28, 2021
-
BUSINESS CNS Alliance with Otsuka Expected to be Long-term: Sumitomo Dainippon Senior Executive
October 28, 2021
-
BUSINESS Sun Pharma Japan to Boost Sales Force, Development to Achieve 1.5-Fold Sales Growth by 2025
October 27, 2021
-
COMMENTARY SGLT2 Inhibitors, Entresto Could Change Paradigm of Treatment of Heart Failure: JHFS Annual Confab
October 26, 2021
-
BUSINESS KM Biologics Eyes COVID-19 Booster Filing as Early as Spring, Trial Start Slated by Year-End
October 26, 2021
-
ORGANIZATION Main Focus of INES Proposal Is Securing Resources to Reward Innovation, Not Macroeconomic Indexing
October 25, 2021
-
BUSINESS Mundipharma Japan Set to Cut into High Production Costs, Boost Profitability to Lure Investments: President
October 22, 2021
-
ACADEMIA Japan Headache Society Clarifies Patients Suitable for CGRP Migraine Meds, No Drug Selection Criteria Given for Now
October 21, 2021
-
REGULATORY Average Price Gap for FY2022 Revision Likely to Be 8% Level or Lower: Wholesalers
October 20, 2021
-
COMMENTARY LDP’s Pharma Study Group at Critical Juncture as Kishida Vows to Rectify Power Balance, Kingpins Retire
October 19, 2021
-
BUSINESS Veklury Now Available in Normal Distribution Channel in Japan
October 19, 2021
-
BUSINESS Alfresa to Introduce Digital-Driven Deliveries at All Offices by August 2024; Test Run Showing Good Results
October 18, 2021
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…